Who are the top 50 leaders in India’s Biopharma industry?

In an effort to publish reliable and useful content for the members of our online community, we gather feedback from the industry to list outtop 50 most influential individuals in the current bio-pharmaceutical industry in India. This ebook is a complimentary effort by our BioPharma India Convention team to thank the industry for their continuous support in the past 13 years. An encouraging amount …

biopharma, biopharmaindia, india, manufacturing, cellculture, culture medium, media, media preparation, single-use, single-use technology, processing trends, biopharmaceutical processing, biopharmaceutical

Download: Powder Culture Media Packaging, Preparation and Market Trends

This whitepaper from Thermo Fisher reviews the impact from recent trends in biopharmaceutical processing on the usage of culture media and its packaging. Current media preparation problems, future trends, and alternatives to media prep practices are discussed. The findings and commentary from on-line survey of 24 large-scale culture media end-users together with in-depth phone interviews are presented to evaluate relevant …

Leaders of Asia — Interview with Anand Tharmaratnam, Senior Vice President & Head of Asia Markets, Quintiles East Asia

How is it like to overseeing the world’s largest CRO’s clinical development and market access businesses across 13 Asia-Pacific countries that account for half the world’s population – including Japan and China, the world’s second- and third-largest biopharmaceutical markets, respectively? It is definitely not a walk in the park for some others but it’s all in a day’s job for …

Building and Sustaining Strategic Relationships – Interview with Samir Shah

Relationships form the basis of any successful partnership. Trust and transparency are but two of the many factors that attribute to a strong and stable relationships. While it is easy to form such relationships, it is an upheaval task that requires consistency, diligence and sheer determination to maintain them. Sometime back, Samir Shah, Chief Operating Officer, PRA Health Sciences joined …

Asia & its patient recruitment potential for clinical trials

In today’s whitepaper release, featured company ClinActis, shares their insight on patient recruitment strategies in Asia and the possible approaches for the different regions in APAC. ______________ According to the 2012 Tufts CSDD study, clinical site activation rates in Asia Pacific are at one of the highest, with 91% of sites successfully progressing through the study start up stages and …

Download White Paper : Engaging Clinical Trial Sites – The Role of the Clinical Trial Liaison

Enrollment in clinical trials is heavily dependent on two very important customers: the research subject and the clinical trial investigator. Research subjects are highly valuable since it is obviously impossible to complete a clinical trial without a willing group of participants. There are many groups and even entire companies that specialize in engaging potential subjects and connecting them to clinical …

Download White Paper : Translating Cancer Genomics for personalized approach to treating cancer

Over the past few decades, the approach to prevention, diagnosis and treatment of cancer has radically shifted from organ-based to morphology-based and most recently, to genetics-based. Personalized or precision medicine (tailoring a treatment for a patient’s particular disease at a precise time point) is being performed every day at different levels in the clinical setting.The study of cancer genomics has …

Download White Paper : Single Use Technology specifically designed for microbial fermentation

Single Use Technology is pretty much the one of the most talked about trend in the BioPharmaceutical Space. Within a doubt, this is one topic that has been constantly asked for by our attendees across the BioPharma Asia Pacific events. As we move quickly into the next phase for the BioPharma Asia Convention 2015, we look at some of the …

Spotlight back on Antibiotics Market

Thought to be undervalued and overshadowed by the bigger revenue draw from blockbuster drug manufacturing, Merck’s ($MRK) recent acquisition of Cubist ($CBST) might have placed a spotlight back to the Antibiotics Market. Unlike its compatriots in the biologic therapeutics market, antibiotics target specifically on bacterial infections. More often than not, the efficacy of antibiotics decreases through the misuse of antibiotics. …